ERBB2 and breast cancer: Since TNBC is characterized by the lack of ER and PR expression, combined with the absence of both overexpression and amplification of the gene encoding HER2 [2,5], the targeted treatment that is effective in the other BC subtypes is futile for TNBC patients [6].